ClinicalTrials.gg
TerminatedNCT02239835Updated Sep 15, 2014

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

A Phase 2 interventional study of Tipranavir (TPV) low dose and Tipranavir (TPV) high dose in HIV Infections, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in HIV Infections by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. HIV Infections · Boehringer Ingelheim.

Enrollment
24th of 46
79 · median 82
Started
1999
with 7 others
Phase 2
12 of 67
none open now
Registered
64th of 67
by date

Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 24th largest by enrollment of the 46 interventional ones that give a count, is one of 8 that started in 1999, is one of 12 in phase 2, and was the 64th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 67 studies in HIV Infections by Boehringer Ingelheim is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 67 studies in HIV Infections by Boehringer Ingelheim as a file.
02

Study summary

Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir (RTV) and to evaluate the dose response of two different doses of TPV in combination with RTV for efficacy and safety.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical failure while on the current PI-containing regimen of indinavir, nelfinavir, or amprenavir
  • In the investigator's opinion, adherence to the present PI-containing regimen
  • Exposure of >=6 months to the current PI therapy
  • Stable PI-containing regimen, i.e., receiving the current two reverse transcriptase inhibitors (RTIs) for at least 2 months prior to study entry
  • -1 RNA >=1000 copies/mL (assayed using the Amplicor polymerase chain reaction (PCR) method at the initial screening visit)
  • No limit in at the initial screening
  • At least two new nucleoside reverse transcriptase inhibitor (NRTI) options available
  • Age >=18 years
  • Acceptable screening laboratory test values that indicated adequate baseline organ function at the time of screening. Acceptable laboratory test values consisted of the following: severity \<=Grade 1 (ACTG Grading Scale). Stable Grade 2 abnormalities were permitted if the values had been demonstrated and documented for at least >=2 months. All laboratory values >Grade 2 were subject to approval by the P\&U Clinical Program Leader or designated personnel and subsequently by the BI designated personnel
  • Acceptable medical history, physical examination, , and chest radiograph prior to entry into the treatment phase of the study
  • Use of a barrier method of birth control for at least 30 days prior to study drug administration, during the study, and 30 days after study completion
  • Ability to swallow numerous tablets and capsules without difficulty
  • Ability to understand and provide . Minors had to have approval of a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Treatment with more than one PI-containing regimen
  • active or acute (onset within the month previous to study entry) medical problems, including the following: opportunistic infections, e.g., active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis, or cytomegalovirus; nonopportunistic diseases, including but not limited to the following: progressive multifocal leukoencephalopathy, lymphoma, or requiring systemic therapy
  • Prior exposure (>7 days) to tipranavir, saquinavir, or ritonavir
  • History of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair adherence to the protocol
  • Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and including the following: rifabutin, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin
  • to tipranavir, saquinavir, or ritonavir
  • Use of interferons, interleukins, vaccines, or any active immunizations within 30 days of study entry
  • Taking of any medication with the exception of adefovir dipivoxil (Preveon™) within 30 days of study entry
  • Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been negative within 14 days of study entry)
  • Evidence of substance abuse, which in the investigator's opinion could affect adherence to the protocol
  • In the investigator's judgment, inability to comply with the protocol requirements for reasons other than those specified
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    TPV low dose + RTV low dose

    Drug: Tipranavir (TPV) low dose · Drug: Ritonavir low dose

  • Experimental
    TPV high dose + RTV low dose

    Drug: Tipranavir (TPV) high dose · Drug: Ritonavir low dose

  • Active comparator
    SQV + RTV high dose

    Drug: Ritonavir high dose · Drug: Saquinavir

Interventions

  • DrugTipranavir (TPV) low dose
  • DrugTipranavir (TPV) high dose
  • DrugRitonavir low dose
  • DrugRitonavir high dose
06

What researchers measure

Primary outcomes

  1. Change from baseline in plasma HIV-1 RNA concentrations

    Time frame: Week 16, 24 and 48

  2. Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ)

    using the Roche Amplicor HIV Monitor™ Method \[limit of detection (LD) 400 copies/mL\] and the Roche Amplicor UltraSensitive Method™ (LD 50 copies/mL)

    Time frame: up to 96 weeks

  3. Number of patients with treatment-emergent and drug-related adverse events (AEs)

    Time frame: up to 96 weeks

  4. Number of patients with serious adverse events (SAEs)

    Time frame: up to 96 weeks

  5. Number of patients with grade 3 and 4 laboratory abnormalities

    Time frame: up to 96 weeks

Secondary outcomes

  1. Change from baseline in cluster of differentiation (CD) 4+ cell count

    Time frame: Week 16, 24 and 48

  2. Time to virologic failure

    defined as plasma HIV-1 RNA values \>400 copies/mL at two consecutive time points 2 to 4 weeks apart

    Time frame: after week 16

  3. Occurrence of new or recurring AIDS-defining illnesses

    Time frame: up to 96 weeks

  4. Occurrence of HIV-1 related illness

    Time frame: up to 96 weeks

  5. Occurrence of death

    Time frame: up to 96 weeks

  6. Time to new or recurring AIDS-defining illnesses

    Time frame: up to 96 weeks

  7. Time to HIV-1 related illness

    Time frame: up to 96 weeks

  8. Time to death

    Time frame: up to 96 weeks

  9. Change from baseline in blood glucose

    Time frame: up to 96 weeks

  10. Change from baseline in cholesterol

    Time frame: up to 96 weeks

  11. Change from baseline in high density lipoprotein (HDL)

    Time frame: up to 96 weeks

  12. Change from baseline in triglycerides

    Time frame: up to 96 weeks

  13. Time to virologic response

    Time frame: up to 96 weeks

  14. Trough plasma tipranavir concentrations

    Time frame: up to week 24

  15. Sequence-based HIV-1 analysis (genotyping) and drug susceptibility assays (phenotyping)

    Time frame: Baseline and week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1999 and a primary completion of Nov 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Sep 15, 2014
Start
Dec 1999
Primary completionActual
Nov 2001
Last update
Sep 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02239835
Responsible party
Sponsor
First posted
Sep 15, 2014
Start date
Dec 1999
Primary completion
Nov 2001
Last update
Sep 15, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion